Back to Feed
Fintech▲ 70
Muzastotug Data Shows Improved Durability
Globenewswire·
Updated data from a Phase 1b/2 study combining muzastotug with KEYTRUDA® in late-line patients with microsatellite stable colorectal cancer demonstrates improved durability of response. The results indicate a dose-dependent efficacy, with muzastotug achieving a 31% overall response rate in the combined 20 mg/kg cohort. These findings suggest a promising therapeutic benefit for patients with limited treatment options. Further investigation into this combination therapy is warranted to fully assess its potential in treating advanced colorectal cancer.
Tags
product
regulation
Original Source
Globenewswire — www.globenewswire.com